Patient
Resource Center

Learn about Medicare and insurance coverage options that may apply to the Afirma test.

A guide to the Afirma Thyroid test explaining how it works, insurance coverage, and financial assistance.

Prepare for your appointment with questions to ask your doctor about thyroid nodule diagnosis and the Afirma test.

Hear how the Afirma test helped a doctor and patient avoid an unnecessary surgery by ruling out cancer while maintaining quality of life.

Hear one patient’s experience with the physical and emotional impact of a thyroidectomy, and why accurate testing matters.

For patients with an indeterminate nodule that was found to be Benign by the Afirma test.

For patients with an indeterminate nodule that was found to be Suspicious by the Afirma test.

For patients diagnosed with an indeterminate nodule by Thyroid Cytopathology Partners, the Afirma test classified it as Benign.

For patients diagnosed with an indeterminate nodule by Thyroid Cytopathology Partners, the Afirma test classified it as Suspicious.

Learn about Medicare and insurance coverage options that may apply to the Decipher Prostate test.

A urologist shares his very personal story of being diagnosed with prostate cancer and using the Decipher Prostate test in his clinical practice for his patients.

For patients with localized prostate cancer who have not received radiation or hormone therapy before biopsy.

For patients with localized prostate cancer after surgery, before radiation or hormone therapy.

For patients with metastatic prostate cancer. 
The test uses the most recent biopsy or surgery sample before starting radiation or hormone therapy.

Learn about Medicare coverage and self-pay options may apply to the Decipher Bladder test.

A guide to the Decipher Bladder test explaining how it works, insurance coverage, and financial assistance.​

The report provides the molecular subtype of your tumor and information to help you and your doctor choose the treatment plan that’s right for you.

Learn how Prosigna helps assess your 10-year breast cancer recurrence risk to support personalized treatment planning.